Sleep aid

摘要

On 22 May, advisers to US drug regulators recommended approval of a first-in-class therapy for insomnia, but proposed its use only at low doses. The drug, called suvorexant, is made by Merck, a pharmaceutical company in Whitehouse Station, New Jersey. If approved, it will be the first insomnia drug to block orexin, a neurotransmitter that regulates sleep-wake cycles.